Caribou Biosciences' CAR-T Therapy Receives FDA RMAT Designation

Caribou Biosciences (CRBU) shares rose 9% premarket after the FDA granted RMAT designation for its CAR-T cell therapy, CB-011. The therapy, an allogeneic anti-BCMA CAR-T cell therapy, is currently in clinical trials. The RMAT designation is a regulatory expedited pathway for therapies addressing a serious or life-threatening disease where no satisfactory alternative treatment is available.